BioSpace News Archive

Nu-Med Plus, Inc., a medical device company which investigates and develops applications and devices for nitric oxide delivery in the medical field, announced that the United States Patent and Trademark Office has allowed the issuance of a patent for a single-use or short-term use nitric oxide inhaler.

Axovant Gene Therapies, Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies for neurological diseases, today announced that Parag Meswani, Pharm.D., SVP of Commercial Strategy and Operations, will present at the Jefferies Global Virtual Healthcare Conference. Presentation Details: Date: Thursday, June 4, 2020 Time: 3:00 PM EDT Webcast link: http://wsw.com/webcast/jeff

Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use, today announced that the Company will present at the Jefferies 2020 Virtual Healthcare Conference, Wednesday, June 3, 2020 at 8:00 a.m. ET. To access the live webcast of Paratek’s

Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced the expansion of its Sponsored Research Agreement (SRA) with the University of Pennsylvania (Penn). The

Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates, today announced that Dr. Behzad Aghazadeh, Executive Chairman, is scheduled to participate in virtual fireside chats at the following healthcare conferences: Jefferies Virtual Healthcare Conference on Thursday, June 4 at 3:30 p.m. Eastern Time Goldman Sachs 41st Annual Global Healthcar

Histogen Inc., a regenerative medicine company with a novel biological platform that replaces and regenerates tissues in the body, announced the appointment of Susan A. Knudson as Executive Vice President and Chief Financial Officer.

X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced that its management team will present and conduct one-on-one meetings virtually at the Jefferies Global Healthcare Conference 2020 and BMO 2020 Prescriptions for Success Healthcare Conference. Details are as follows: Conference: Jefferies Global Healthcare

Syapse, today announced $30 million in new equity funding to accelerate the creation and use of real-world evidence in oncology. The financing was led by Revelation Alpine, LLC, with participation from existing investors including Amgen Ventures, Ascension Ventures, Intermountain Ventures, Merck Global Health Innovation Fund, Roche Finance Ltd, Safeguard Scientifics and Social Capital. Revelation Alpine’s Managing Partner Zack Scott, MD will join

Interim results showed Auxora plus standard of care improved time to recovery and reduced ventilator use in patients compared to standard of care alone

IntelGenx Technologies Corp. (TSX-V:IGX) (OTCQB:IGXT) (“ IntelGenx ” or the “ Corporation ”) today announced that it intends to issue shares of common stock (“ Common Shares ”) of the Corporation in payment of the outstanding $7,577,000 aggregate principal amount of the Corporation’s 8.00% convertible unsecured subordinated debentures due June 30, 2020 (the “ Debentures ”). Under the terms of the trust indenture governing the Debentures